News archive
Showing 654 results
May 2008
-
Media Release
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
- RECORD-1 trial shows RAD001 reduces risk of disease progression by 70%- RAD001 is first and only drug to show significant benefit after failure of approved therapies Sutent(R) or Nexavar(R),** with… -
Media Release
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
-
Media Release
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
- Unprecedented amount of research reflects depth and breadth of collaboration with investigators worldwide to develop new treatments for diverse forms of cancer- Plenary session to highlight impact… -
Media Release
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
March 2008
-
Media Release
VIDEO: Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
- Post-unblinding analysis of MA-17 trial data provides evidence for potential benefit of starting Femara up to seven years after finishing tamoxifen- Femara only member of aromatase inhibitor class… -
Media Release
VIDEO: Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
February 2008
-
Media Release
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
- Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus- Everolimus (RAD001) tablet, taken once daily,… -
Media Release
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
January 2008
-
Media Release
Video and Photo: Tekturna HCT®, a Single-tablet Combination of Tekturna®* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
- Tekturna HCT combines first approved direct renin inhibitor with the diuretic hydrochlorothiazide (HCTZ) in a single tablet- Data show combination of Tekturna and HCTZ resulted in significant… -
Media Release
Video and Photo: Tekturna HCT®, a Single-tablet Combination of Tekturna®* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
December 2007
-
Media Release
Photo: New Data Show Gleevec® Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
- Risk of disease progression continues to drop from the second year of treatment; no patients taking Gleevec in sixth year progressed from initial disease phase- Long-term survival trend may suggest… -
Media Release
Photo: New Data Show Gleevec® Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment